Gaston Kris E, Kim Desok, Singh Swaroop, Ford O Harris, Mohler James L
Division of Urology, Department of Surgery, University of North Carolina, Chapel Hill, NC 27599, USA.
J Urol. 2003 Sep;170(3):990-3. doi: 10.1097/01.ju.0000079761.56154.e5.
Black American men experience disproportionate mortality from prostate cancer (CaP) compared with white American men. Differences in outcome may stem from differences within the androgen axis. Since serum testosterone levels appear to be similar by race in men with CaP, we measured and compared androgen receptor (AR) protein expression in malignant and benign prostate tissue from black and white men who underwent radical prostatectomy for clinically localized CaP.
Archived radical prostatectomy specimens obtained from 25 white and 25 black men had AR protein antigen retrieved and immunostained. AR protein expression from CaP and benign tissue was assessed by 2 methods. Automated digital color video image analysis was used to measure the percent area immunostained for AR protein and the intensity of expression (mean optical density). Visual scoring was performed to compare results with automated values.
In black compared with white men malignant nuclei were 27% more likely to immunostain for AR (p = 0.005) and in immunopositive nuclei AR protein expression was 81% greater (p = 0.002). Visual scoring of malignant nuclei revealed that AR immunostaining was significantly increased in black vs white men (171 +/- 40 vs 149 +/- 37, p = 0.048). In immunopositive benign nuclei AR protein expression was 22% greater in black than in white men (p = 0.027). Visual scoring of benign nuclei revealed 20% increased immunostaining in black vs white men, although this difference did not attain statistical significance (p = 0.065). Racial differences in AR protein expression were not explained by age, pathological grade or stage, although serum prostate specific antigen levels were higher in black men (9.7 +/- 7.5 vs 15.5 +/- 12.2 ng/ml, p = 0.049).
AR protein expression was 22% higher in the benign prostate and 81% higher in the CaP of black African compared with white men. CaP may occur at a younger age and progress more rapidly in black than in white men due to racial differences in androgenic stimulation of the prostate.
与美国白人男性相比,美国黑人男性前列腺癌(CaP)死亡率更高。预后差异可能源于雄激素轴的差异。由于患有CaP的男性血清睾酮水平在种族间似乎相似,我们测量并比较了因临床局限性CaP接受根治性前列腺切除术的黑人和白人男性恶性及良性前列腺组织中雄激素受体(AR)蛋白的表达。
从25名白人和25名黑人男性获取的存档根治性前列腺切除术标本进行AR蛋白抗原修复和免疫染色。通过两种方法评估CaP和良性组织中AR蛋白的表达。使用自动数字彩色视频图像分析来测量AR蛋白免疫染色的面积百分比和表达强度(平均光密度)。进行视觉评分以将结果与自动测量值进行比较。
与白人男性相比,黑人男性恶性细胞核免疫染色AR的可能性高27%(p = 0.005),在免疫阳性细胞核中AR蛋白表达高81%(p = 0.002)。对恶性细胞核的视觉评分显示,黑人男性的AR免疫染色明显高于白人男性(171 ± 40 vs 149 ± 37,p = 0.048)。在免疫阳性的良性细胞核中,黑人男性的AR蛋白表达比白人男性高22%(p = 0.027)。对良性细胞核的视觉评分显示,黑人男性的免疫染色比白人男性增加了20%,尽管这种差异未达到统计学意义(p = 0.065)。AR蛋白表达的种族差异不能用年龄、病理分级或分期来解释,尽管黑人男性的血清前列腺特异性抗原水平更高(9.7 ± 7.5 vs 1十五点五± 12.2 ng/ml,p = 0.049)。
与白人男性相比,非洲黑人良性前列腺中AR蛋白表达高22%,CaP中高81%。由于前列腺雄激素刺激存在种族差异,CaP在黑人男性中可能发病年龄更小且进展更快。